Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.
Semin Liver Dis. 2021 May;41(2):136-141. doi: 10.1055/s-0040-1722646. Epub 2021 May 6.
The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.
过去十年，肝癌（HCC）的突破性治疗策略的可用性有所增加。HCC 的肿瘤微环境受各种免疫耐受机制调控；因此，旨在打破肿瘤免疫耐受的治疗策略正成为 HCC 有吸引力的治疗选择。免疫检查点抑制剂在 HCC 中显示出令人印象深刻的疗效，包括在索拉非尼无应答的患者中。免疫检查点抑制剂（抗 PD-1/PD-L1 和 CTLA-4）与抗血管生成药物的协同方法正在蓬勃发展，成为 HCC 的一线治疗方式。
